Results from anavex life sciences landmark phase iib/iii trial of blarcamesine presented at alzheimer's association conference

Oral, once daily blarcamesine significantly slowed clinical decline for early alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events

AVXL Ratings Summary

AVXL Quant Ranking